ZA202402034B - Caix targeting il-12 fusion proteins and methods of use thereof - Google Patents

Caix targeting il-12 fusion proteins and methods of use thereof

Info

Publication number
ZA202402034B
ZA202402034B ZA2024/02034A ZA202402034A ZA202402034B ZA 202402034 B ZA202402034 B ZA 202402034B ZA 2024/02034 A ZA2024/02034 A ZA 2024/02034A ZA 202402034 A ZA202402034 A ZA 202402034A ZA 202402034 B ZA202402034 B ZA 202402034B
Authority
ZA
South Africa
Prior art keywords
fusion proteins
methods
polypeptides
polypeptide
caix targeting
Prior art date
Application number
ZA2024/02034A
Other languages
English (en)
Inventor
Bhatnagar Jaya
Vittal Goswami Arvind
Kumar Tripurana Harish
Nair Pradip
Melarkode Subbaraman Ramakrishnan
Ram Krishn Shiv
Reddy Boreddy Srinivas
Nair Reshmi
K Varshney Avanish
Tan Seng-Lai
Original Assignee
Bicara Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bicara Therapeutics Inc filed Critical Bicara Therapeutics Inc
Publication of ZA202402034B publication Critical patent/ZA202402034B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
ZA2024/02034A 2021-09-17 2024-03-12 Caix targeting il-12 fusion proteins and methods of use thereof ZA202402034B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163245523P 2021-09-17 2021-09-17
PCT/US2022/043762 WO2023043978A2 (en) 2021-09-17 2022-09-16 Caix targeting il-12 fusion proteins and methods of use thereof

Publications (1)

Publication Number Publication Date
ZA202402034B true ZA202402034B (en) 2025-06-25

Family

ID=85603506

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2024/02034A ZA202402034B (en) 2021-09-17 2024-03-12 Caix targeting il-12 fusion proteins and methods of use thereof

Country Status (11)

Country Link
US (1) US20240392031A1 (https=)
EP (1) EP4402158A4 (https=)
JP (1) JP2024534468A (https=)
KR (1) KR20240161081A (https=)
CN (1) CN118369331A (https=)
AU (1) AU2022345103A1 (https=)
CA (1) CA3232632A1 (https=)
IL (1) IL311442A (https=)
MX (1) MX2024003275A (https=)
WO (1) WO2023043978A2 (https=)
ZA (1) ZA202402034B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111630062A (zh) 2017-11-28 2020-09-04 中外制药株式会社 具有可调节的配体结合活性的配体结合分子
WO2025012105A2 (en) * 2023-07-07 2025-01-16 Technische Universitaet Muenchen, In Vertretung Des Freistaates Bayern Muteins of human interleukin 12
WO2025101133A1 (en) * 2023-11-10 2025-05-15 Agency For Science, Technology And Research Interleukin-12 variants and medical uses thereof
WO2025136986A2 (en) 2023-12-18 2025-06-26 Genzyme Corporation Il-12 loss of potency muteins
WO2025205534A1 (ja) * 2024-03-25 2025-10-02 積水メディカル株式会社 免疫測定方法、精度管理方法、標準試料及び免疫測定試薬

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0620648B1 (pt) * 2005-12-30 2022-12-20 Merck Patent Gesellschaft Mit Beschrãnkter Haftung Variante de il-12 p40, proteínas il-12, il-23 e de fusão, composição farmacêutica e uso da mesma
US20210130430A1 (en) * 2018-05-14 2021-05-06 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
IL297186A (en) * 2020-04-17 2022-12-01 Univ Leland Stanford Junior Transgenic il-12 and il-23 polypeptides and their uses

Also Published As

Publication number Publication date
CA3232632A1 (en) 2023-03-23
MX2024003275A (es) 2024-05-07
EP4402158A4 (en) 2025-07-30
AU2022345103A1 (en) 2024-03-28
WO2023043978A3 (en) 2023-09-28
US20240392031A1 (en) 2024-11-28
CN118369331A (zh) 2024-07-19
KR20240161081A (ko) 2024-11-12
WO2023043978A2 (en) 2023-03-23
JP2024534468A (ja) 2024-09-20
IL311442A (en) 2024-05-01
EP4402158A2 (en) 2024-07-24

Similar Documents

Publication Publication Date Title
ZA202402034B (en) Caix targeting il-12 fusion proteins and methods of use thereof
PH12020551907A1 (en) Antagonizing cd73 antibody
WO2019241430A3 (en) Antibody-oligonucleotide conjugates
EA201992765A1 (ru) Белки на основе антител с привитым цитокином и способы их применения в лечении рака
WO2020072821A3 (en) Il-12 heterodimeric fc-fusion proteins
JOP20200313A1 (ar) أجسام مضادة dll3-cd3 ثنائية الخاصية
MX2021011653A (es) Composiciones inmunoterapeuticas y uso de las mismas.
MY208638A (en) Anti-steap1 antigen-binding protein
WO2021181233A3 (en) Cd80-fc fusion protein and uses thereof
EP4527466A3 (en) Anti-dll3 chimeric antigen receptors and uses thereof
MX2025012685A (es) Anticuerpos para claudin6 y metodos para tratar el cancer
WO2019209965A3 (en) Interleukin 12 fusion proteins, and compositions and therapeutic methods thereof
WO2022082073A3 (en) Compositions and methods for muc18 targeting
CY1108387T1 (el) Ανταγωνιστες ανασυνδυασμενης il-18 χρησιμοι στη θεραπεια παθησεων που εμφανιζονται με διαμεσολαβηση της il-18
MY206284A (en) Anti-cd63 antibodies, conjugates, and uses thereof
ZA202203254B (en) Immunocytokine comprising heterodimeric protein complex based on il-15/il-15rα
MX2024007966A (es) Anticuerpos anti-tslp novedosos.
WO2021222150A3 (en) Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
WO2021262910A3 (en) Tubulysins and protein-tubulysin conjugates
MX2023011268A (es) Anticuerpos upar y proteínas de fusión con estos.
MX2022014161A (es) Vacunas contra sars-cov-2.
WO2022197890A8 (en) Anti-alpp/alppl2 antibodies and antibody-drug conjugates
WO2024086617A3 (en) Ph-dependent anti-cd3 antibodies and methods relating thereto
MX2025005092A (es) Anticuerpo anti-trem2 y usos del mismo
WO2024030856A3 (en) Immunomodulatory proteins and related methods